Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx Discounts Do Not Require Restrictive Formularies, PhRMA Tells USP

Executive Summary

Medicare prescription drug plan sponsors will be able to negotiate significant discounts even under a model drug classification system that includes a large number of categories and classes, the Pharmaceutical Research & Manufacturers of America said

You may also be interested in...



PBMs’ Medicare Formulary Lobbying Takes On New Dimensions

The Pharmaceutical Care Management Association's efforts to ensure the Medicare model formulary guidelines will enable pharmacy benefit managers to negotiate deep discounts on drugs have expanded to include print advertising and direct appeals to the Centers for Medicare & Medicaid Services

PBMs’ Medicare Formulary Lobbying Takes On New Dimensions

The Pharmaceutical Care Management Association's efforts to ensure the Medicare model formulary guidelines will enable pharmacy benefit managers to negotiate deep discounts on drugs have expanded to include print advertising and direct appeals to the Centers for Medicare & Medicaid Services

USP Formulary Guide Needs Overhaul To Meet Access Goal, PhRMA, BIO Say

The U.S. Pharmacopeia should completely overhaul its draft model formulary guidelines for Medicare Part D in order to fulfill its task of creating guidelines that prevent health plans from discriminating against certain Medicare beneficiaries, PhRMA and BIO said

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044623

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel